A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease

Detalles del proyecto

EstadoFinalizado
Fecha de inicio/Fecha fin6/14/17 → 1/11/23

Financiación

  • AbbVie Incorporated: 953.210,00 US$